Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer

By afschroeder • November 9, 2025

LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K. Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer. Oncologist. 2025 Nov 7:oyaf371. doi: 10.1093/oncolo/oyaf371. Epub ahead of print. PMID: 41206668.

Tags: breast cancer, Endocrinology, extended-interval dosing, Hematology/Oncology, immune-related adverse events, immunotherapy, pembrolizumab, Publications

A Spanish-language educational intervention to enhance diabetes outcomes among existing continuous glucose monitor users in a federally qualified health care center

Tavares M, Khoshbin K, Solorzano W, Scarlett L, Santana C, Lopez R, Villanueva GP, Escobar B, Mangual KS, Pavlish C, Bush NJ, Moin T, Everett[...]

Enhancing mental and physical health of women through engagement and retention (EMPOWER) 3.0 QUERI: study protocol for a cluster-randomized hybrid type 3 implementation-effectiveness trial

Hamilton AB, Farmer MM, Bean-Mayberry B, Moin T, Lang A, Adams L, Chanfreau C, Fenwick K, Canelo I, Oberman R, Finley EP; EMPOWER 3.0 QUERI[...]

Mitochondrial calcium regulates lipid metabolism by modulating tethering of mitochondria to lipid droplets

Acin-Perez R, Assali EA, Veliova M, Ngo J, Brownstein AJ, Villalobos F, Petcherski A, Hernansanz-Agustin P, Kim-Vasquez D, Xu S, Tamboline M, Silva RM, Upcher[...]